Non-GLP-1 obesity drugs are emerging in the market, with this landscape expected to surge 50-fold, generating $15.5bn in 2031.
Beyond GLP-1Rs: emerging targets poised to gain share of obesity market
Non-GLP-1 obesity drugs are emerging in the market, with this landscape expected to surge 50-fold, generating $15.5bn in 2031.
أعلنت منظمة الصحة العالمية، الأحد، عن وفاة ثلاثة أشخاص وإصابة ثلاثة آخرين على الأقل، إثر تفشي فيروس هانتا على متن سفينة سياحية تبحر في المحيط الأطلسي. …
EHRs not only document care but can also act as a financial engine to bridge the gap between patient care and prompt reimbursement. Here’s how to …
There are many reasons to revolt against the federal government’s regressive policies today. The enormous threat to the quality of our lives, and our children’s, is …
White House National Economic Council Director Kevin Hassett on Sunday said that energy shocks from the Iran war will affect airline profits for at least a …